Dennis Ding
Stock Analyst at Jefferies
(3.89)
# 1,812
Out of 4,399 analysts
91
Total ratings
49.4%
Success rate
10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $40 | $33.58 | +19.12% | 3 | May 27, 2026 | |
| SGP SpyGlass Pharma | Maintained: Buy | $62 | $18.06 | +243.30% | 4 | May 19, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $125 | $85.71 | +45.84% | 9 | May 6, 2026 | |
| ESPR Esperion Therapeutics | Downgraded: Hold | $5 → $3.28 | $3.14 | +4.46% | 6 | May 4, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $20.29 | +8.45% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $9.82 | +307.33% | 1 | Mar 19, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $18 → $30 | $28.41 | +5.60% | 16 | Feb 9, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $8 → $15 | $5.61 | +167.38% | 6 | Jan 27, 2026 | |
| ABUS Arbutus Biopharma | Maintained: Buy | $7 | $4.12 | +69.90% | 4 | Dec 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintained: Hold | $15 → $26 | $23.76 | +9.43% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $29.32 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $18 | $31.18 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $55 | $34.32 | n/a | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.66 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $22.26 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $3.04 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $2.95 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $15.26 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $2.71 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $78.12 | n/a | 4 | Feb 14, 2023 |
Teva Pharmaceutical Industries
May 27, 2026
Maintained: Buy
Price Target: $40
Current: $33.58
Upside: +19.12%
SpyGlass Pharma
May 19, 2026
Maintained: Buy
Price Target: $62
Current: $18.06
Upside: +243.30%
Rhythm Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $125
Current: $85.71
Upside: +45.84%
Esperion Therapeutics
May 4, 2026
Downgraded: Hold
Price Target: $5 → $3.28
Current: $3.14
Upside: +4.46%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $20.29
Upside: +8.45%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $9.82
Upside: +307.33%
Roivant Sciences
Feb 9, 2026
Maintained: Buy
Price Target: $18 → $30
Current: $28.41
Upside: +5.60%
Ardelyx
Jan 27, 2026
Maintained: Buy
Price Target: $8 → $15
Current: $5.61
Upside: +167.38%
Arbutus Biopharma
Dec 11, 2025
Maintained: Buy
Price Target: $7
Current: $4.12
Upside: +69.90%
Mineralys Therapeutics
Sep 3, 2025
Maintained: Hold
Price Target: $15 → $26
Current: $23.76
Upside: +9.43%
Jun 11, 2025
Maintained: Buy
Price Target: $45
Current: $29.32
Upside: n/a
May 29, 2025
Maintained: Hold
Price Target: $20 → $18
Current: $31.18
Upside: n/a
Jan 21, 2025
Upgraded: Buy
Price Target: $55
Current: $34.32
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $1.66
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $22.26
Upside: n/a
Sep 3, 2024
Maintained: Hold
Price Target: $8 → $6
Current: $3.04
Upside: n/a
Jul 17, 2024
Maintained: Hold
Price Target: $1
Current: $2.95
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $15.26
Upside: n/a
Jul 13, 2023
Maintained: Buy
Price Target: $18
Current: $2.71
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $78.12
Upside: n/a